Euroseas Ltd. Reports Results for the Nine-Month Period and Quarter Ended September 30, 2024, Declares Quarterly Dividend and Announces Order for the Construction of Two Fuel-Efficient 4,300 TEU Containerships
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia